 Home > Active Ingredient News > Antitumor Therapy > JCO: Comparison of the efficacy of two adjuvant treatments for patients with stage I HER2+ breast cancer

JCO: Comparison of the efficacy of two adjuvant treatments for patients with stage I HER2+ breast cancer

 Last Update: 2021-06-10
 Source: Internet
 Author: User

Tags

propranolol 80 mg

1 4 water

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

About 15%-20% of aggressive early breast cancer patients overexpress human epidermal growth factor receptor 2 (HER2), and HER2 overexpression is associated with a higher recurrence rate than HER2 negative.

The recurrence rate of breast cancer stage I HER2-positive breast cancer is between 10% and 30%

The purpose of the ATEMPT test is to determine whether trastuzumab emtansine (T-DM1) is less toxic than paclitaxel + trastuzumab (TH) in the treatment of stage I HER2-positive breast cancer, and obtains clinically acceptable results.

Recruited patients with stage I breast cancer diagnosed as HER2-positive, randomly assigned to T-DM1 group or TH group at 3:1, and received T-DM1 (3.

Survival prognosis of patients treated with T-DM1: A 3-year iDFS; B 3-year RFI; C iDFS for patients with different tumor sizes; D iDFS for patients with different HR status

A total of 497 patients were recruited and received protocol treatment (383 in the T-DM1 group and 114 in the TH group).

The incidence of CRT in the T-DM1 group and TH group was 46% and 47%, respectively .

Overall QOL of patients in the two treatment groups

In summary, the results of this study show that for patients with HER2-positive stage I breast cancer, compared with paclitaxel combined with trastuzumab therapy, adjuvant T-DM1 therapy can achieve an excellent 3-year non-invasive disease survival rate for one year.

For patients with HER2-positive stage I breast cancer, compared with paclitaxel combined with trastuzumab therapy, adjuvant T-DM1 treatment for one year can obtain an excellent 3-year non-invasive disease survival rate without increasing clinically relevant toxic events Incidence rate.

Original source:

Tolaney Sara M,Tayob Nabihah,Dang Chau et al.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.